Covid cases hit 100m globally

Oxford-AstraZeneca vaccine was approved for use in the UK

ISARIC evidence forum: Non-Invasive ventilation strategies in COVID-19

ISARIC & GLOPID-R co-hosted: Long COVID forum – 9 & 10 December

We could add small thumbnails, like this: 

Pfizer-BioNTech vaccine was approved for use in the UK

ISARIC evidence forum: How India is identifying best practice in the use of corticosteroids in COVID-19

ISARIC global long covid study launch: 

ISARIC Global COVID19 Paediatric Follow up working group launched

100K milestone – patient data have been entered on ISARIC’s clinical data collection tool!

ISARIC COVID-19 Adult Follow Up Global working group launched

Dexamethasone is first proven treatment against COVID- recovery trials

ISARIC global CRF for children with MIS finalised (MIS-C)

ISARIC4C UK CCP Tier 1 Follow up survey finalised

ISARIC global CRF module for ICU and Critical Illness finalised

trial for Azithromycin recruits first patient

WHO resumes hydroxychloroquine study for Covid-19

UK CCP has now recruited over 52,000 patients

letter of concern signed by Peter & Piero sent to the Lancet questioning results hydroxychloroquine study for Covid-19 (Surgisphere)

the Guadian publishes investigation into Surgisphere study

WHO halts hydroxychloroquine trial based on Surgisphere study

Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 WHO Working Group supported by ISARIC

remdesivir trial published

COVID-19 Rapid Evidence Reviews Group (CORRE) launched

Need some text here

Number of cases worldwide reaches 1M

Recovery trial starts recruiting patients

RAPID version of CRF goes live on REDCap

Discovery trial starts recruiting

Bin Cao trial published

First patient data entered on ISARIC Data Platform

First patients enrolled in remdesivir Randomised control trial in Wuhan.

CCP UK recruits first participants

APPRISE launches observational study based on ISARIC CCP

Global Support Centre supports colleagues in China. Both are heavily involved in the outbreak response (design and implementation of a trial within Wuhan; Lopinavir-ritonavir trial)

Development and dissemination of an nCoV Clinical Characterisation Protocol (CCP) which is a flexible research protocol enabling collection of data and biological samples by investigators who wish to run their own observational studies.

CCP-UK study activated and now open to enrolment in NHS Trusts

WHO launches new data platform for anonymized 2019-nCoV clinical data

WHO and ISARIC agree on global platform for anonymized 2019-nCoV clinical data

The WHO Committee agreed that the outbreak now meets the criteria for a Public Health Emergency of International Concern.

ISARIC endorsed studies led by Genomicc and Remapcap

ISARIC n-CoV resources have been downloaded by 26 countries

Household transmission investigation protocol for 2019-novel coronavirus (2019-nCoV) infection launched on WHO website.

ISARIC n-CoV Resources page launched

Randomised Control Trial registered on Chinese Trial Registry. A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus infection.

Statement released: not declared Public Health Emergency of International Concern. END.

ISARIC Newsflash to all members/partners – Outbreak of Novel Coronavirus

China publicly shared the genetic sequence of COVID-19

Professor Horby sends list of SARI sites amongst ISARIC collaborators in China to WHO

Discussions with WHO regarding the development of Case Report Forms

SARI collaborator Bin Cao reports that he has been in Wuhan for several days – seeing patients and developing diagnosis and treatment guidelines. END.

The WHO China Country Office was informed of cases of pneumonia of unknown etiology (unknown cause) detected in Wuhan City, Hubei Province of China